Symbol="CUE"
AssetType="Common Stock"
Name="Cue Biopharma"
Description="Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts."
CIK="1645460"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="21 ERIE STREET, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="125437000"
EBITDA="-52093224"
PERatio="None"
PEGRatio="None"
BookValue="1.052"
DividendPerShare="0"
DividendYield="0"
EPS="-1.15"
RevenuePerShareTTM="0.044"
ProfitMargin="0"
OperatingMarginTTM="-29.52"
ReturnOnAssetsTTM="-0.418"
ReturnOnEquityTTM="-0.98"
RevenueTTM="1789200"
GrossProfitTTM="1245200"
DilutedEPSTTM="-1.15"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="52.15"
AnalystTargetPrice="10"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="13.03"
PriceToBookRatio="2.501"
EVToRevenue="9.35"
EVToEBITDA="-1.9"
Beta="1.982"
num_52WeekHigh="5.12"
num_52WeekLow="2.18"
num_50DayMovingAverage="3.715"
num_200DayMovingAverage="3.51"
SharesOutstanding="44959500"
DividendDate="None"
ExDividendDate="None"
symbol="CUE"
open="2.90"
high="2.90"
low="2.63"
price="2.79"
volume="496782.00"
latest_trading_day="2023-08-25"
previous_close="2.89"
change="-0.10"
change_percent="-3.4602%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="42"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="58"
Volume_recent_avg="407020"
Change_recent_avg="-0.03"
Delta_recent_avg="0.26"
Variance_recent_avg="0.13"
Change_ratio_recent_avg="-0.94"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="58"
Aroon_momentum_negative="42"
image_negative_thumbnail_id_1="1104"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0137.jpeg"
image_negative_thumbnail_id_2="490"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0115.jpeg"
image_neutral_thumbnail_id_1="542"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0057.jpeg"
image_neutral_thumbnail_id_2="560"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0039.jpeg"
image_positive_thumbnail_id_1="707"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0001.jpeg"
image_positive_thumbnail_id_2="702"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0006.jpeg"
image_professor_thumbnail_id_1="1191"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0025.jpeg"
image_professor_thumbnail_id_2="1170"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0004.jpeg"
